Clinical trials: Incretins
Insulin Secretion
Regulation of Insulin Secretion by the GLP-1 Receptor
AIM2: The purpose of Aim-2 of this study is to determine the role of basal GLP-1 action on the beta-cell response to insulin resistance.
- Trial name
- NCT02844907
- Testing
- Exendin (9-39), Dexamethasone, Hyperglycemic Clamp
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Obesity
Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients
Our overall goal is to determine the effect of Phentermine and Topiramate ER on gastric emptying, gastric accommodation, satiety, and satiation in obese participants.
- Trial name
- NCT01834404
- Testing
- Phentermine-Topiramate ER
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients with type 2 diabetes…
- Trial name
- DM200-101 (NCT00638716)
- Testing
- CJC-1134-PC
- Where
- Canada
- Volunteers
- 122 people
- Sponsor
- ConjuChem
Type 2 Diabetes
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
Objectives: To quantify differences in control of glycemia (primary objective) and the secretion of endogenous incretin hormones (secondary objective) comparing sitagliptin or placebo added to pre-existing therapy with…
- Trial name
- NCT01937598
- Testing
- Mixed meal test, Liraglutide, Sitagliptin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Michael A. Nauck
Type 1 Diabetes, Hypoglycemia
Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
Hypoglycaemia is a well-known complication of insulin treated diabetes. The counterregulatory response to hypoglycaemia, with glucagon as the most important mediator, is initially diminished within a few years of onset of Type 1…
- Trial name
- DARE (NCT01272583)
- Testing
- Sitagliptin
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Obesity
Sugar-replacement Sweeteners, and Blood Sugar Control
Several sugar-replacement sweeteners are currently on the market, including saccharine (ex. Sweet'N Low), aspartame (ex. Equal), and sucralose (ex. Splenda).
- Trial name
- SIR (NCT01128829)
- Testing
- Water, Sucralose
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diabetes Mellitus, Type 2, Diabetes
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus insulin detemir in combination with insulin aspart and metformin in subjects with very…
- Trial name
- SIMPLE (NCT01966978)
- Testing
- Metformin, Detemir, Liraglutide
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- University of Texas Southwestern Medical Center
Morbid Obesity, Metabolic Syndrome X
Randomized Comparison of Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity
Bariatric surgery is the most effective treatment for morbid obesity. Roux-en-Y gastric bypass (RYGB) is a bariatric procedure with known safety and effectiveness.
- Conditions
- Morbid Obesity, Metabolic Syndrome X, Diabetes Mellitus, Dyslipidemia
- Trial name
- NCT01806506
- Testing
- Laparoscopic sleeve gastrectomy, Roux-en-Y Gastric Bypass
- Where
- Poland
- Volunteers
- 72 people
- Sponsor
- Medical University of Warsaw
Type 2 Diabetes
Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult Indian patients with inadequate glycaemic control with diet and…
- Trial name
- NCT00918879
- Testing
- Saxagliptin
- Where
- 9 sites in India
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
To compare the risk of acute pancreatitis in patients with Type 2 diabetes mellitus (T2DM) newly initiating empagliflozin to that of patients newly initiating other oral non-incretin/non-Sodium glucose co-transporter-2 inhibitor…
- Trial name
- NCT05162014
- Testing
- empagliflozin, Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
- Where
- Germany
- Volunteers
- 494,679 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Changes in Bone Turnover With Increased Incretin Hormone Exposure
The purpose of this study is to determine if the use of sitagliptin increases bone formation and reduces bone turnover in postmenopausal women with type 2 diabetes.
- Trial name
- DRTC (NCT01374568)
- Testing
- sitagliptin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
- Trial name
- NCT04881760
- Testing
- LY3437943
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Healthy
Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
Pioglitazone, a drug used in treatment of type 2 diabetes has been shown to improve insulin sensitivity in skeletal muscle, liver, and fat cells.
- Conditions
- Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
- Trial name
- PIO-EX (NCT00845182)
- Testing
- Pioglitazone, Exenatide, Pioglitazone and Exenatide
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients who are currently on…
- Trial name
- NCT00674466
- Testing
- 1.5 mg or 2.0 mg CJC-1134-PC
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- ConjuChem
Type 2 Diabetes
Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated…
- Trial name
- NCT00661362
- Testing
- Saxagliptin, Metformin
- Where
- 30 sites in China, India and 1 more
- Volunteers
- 570 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients with inadequate glycaemic control with diet and…
- Trial name
- NCT00698932
- Testing
- Saxagliptin
- Where
- 30 sites in China, India and 2 more
- Volunteers
- 568 people
- Sponsor
- AstraZeneca
Diabetes, Hyperglycemia
Insulin Secretion in Diabetes Before and After Glycemic Control
The objective of this project is to understand defects in insulin secretion that contribute to abnormal glucose metabolism in patients with diabetes.
- Trial name
- NCT00469833
- Testing
- insulin glargine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Type 2 Diabetes
The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
The goal of this study was to determine the metabolic mechanism for a certain type medication's ability to lower blood sugar after a meal in Type 2 Diabetics, in order to develop a better understanding of it's potential role in…
- Trial name
- NCT00951899
- Testing
- Colesevelam, Diet, Metformin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Type 2 Diabetes
Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.
- Trial name
- NCT00614939
- Testing
- Saxagliptin
- Where
- 74 sites in United States, Belarus and 12 more
- Volunteers
- 572 people
- Sponsor
- AstraZeneca